文献速递临床试验与 GCP流行病学与生物统计

四药与三药联合抗逆转录病毒疗法初治HIV感染者的系统评价与Meta分析

Quadruple versus triple combination antiretroviral therapies for treatment naive people with HIV: systematic review and meta-analysis of randomised controlled trials.
PubMed 文献 · BMJ · 2019-07-08

结果显示两组在病毒学抑制、免疫学应答、病毒学失败、新发艾滋病定义事件、死亡及严重不良反应方面均无显著差异,不支持四药方案优于三药方案,支持现行指南推荐三药方案作为一线治疗。

要点

  • 四药联合方案在初治HIV感染者中未显示优于三药联合方案。
  • 三药方案仍为指南推荐的一线治疗选择。
  • 仅在获得新的抗逆转录病毒药物类别时,才需重新评估四药方案。

核心结论

  • 在初治HIV感染者中,四药联合抗逆转录病毒疗法的效果不优于三药联合疗法。
  • 该结果支持现行指南推荐三药方案作为一线治疗。

主要发现

  • 以三药疗法为参照,四药疗法组检测不到HIV-1 RNA的风险比为0.99(95%CI 0.93至1.05)。
  • 病毒学失败的风险比为1.00(95%CI 0.90至1.11),新发艾滋病定义事件的风险比为1.17(95%CI 0.84至1.63)。
  • 死亡的风险比为1.23(95%CI 0.74至2.05),严重不良反应的风险比为1.09(95%CI 0.89至1.33)。
  • 两组CD4 T细胞计数增加的均数差为-19.55 cells/μL(95%CI -43.02至3.92)。
  • 无论具体联合抗逆转录病毒治疗方案如何,结果基本一致,且在所有亚组和敏感性分析中稳健。

临床怎么用

  • 临床实践中应继续将三药联合抗逆转录病毒疗法作为初治HIV感染者的一线方案。
  • 不推荐常规使用四药联合方案替代三药方案,除非有新证据支持特定人群获益。

局限性

  • 本研究不能排除当新的抗逆转录病毒药物类别可用时四药联合疗法可能优于三药联合疗法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the effects of four drug (quadruple) versus three drug (triple) combination antiretroviral therapies in treatment naive people with HIV, and explore the implications of existing trials for clinical practice and research. DESIGN: Systematic review and meta-analysis of randomised controlled trials. DATA SOURCES: PubMed, EMBASE, CENTRAL, Web of Science, and the Cumulative Index to Nursing and Allied Health Literature from March 2001 to December 2016 (updated search in PubMed and EMBASE up to June 2018); and reference lists of eligible studies and related reviews. STUDY SELECTION: Randomised controlled trials comparing quadruple with triple combination antiretroviral therapies in treatment naive people with HIV and evaluating at least one effectiveness or safety outcome. REVIEW METHODS: Outcomes of interest included undetectable HIV-1 RNA, CD4 T cell count, virological failure, new AIDS defining events, death, and severe adverse effects. Random effects meta-analyses were conducted. RESULTS: Twelve trials (including 4251 people with HIV) were eligible. Quadruple and triple combination antiretroviral therapies had similar effects on all relevant effectiveness and safety outcomes, with no point estimates favouring quadruple therapy. With the triple therapy as the reference group, the risk ratio was 0.99 (95% confidence interval 0.93 to 1.05) for undetectable HIV-1 RNA, 1.00 (0.90 to 1.11) for virological failure, 1.17 (0.84 to 1.63) for new AIDS defining events, 1.23 (0.74 to 2.05) for death, and 1.09 (0.89 to 1.33) for severe adverse effects. The mean difference in CD4 T cell count increase between the two groups was -19.55 cells/μL (-43.02 to 3.92). In general, the results were similar, regardless of the specific regimens of combination antiretroviral therapies, and were robust in all subgroup and sensitivity analyses. CONCLUSION: In this study, effects of quadruple combination antiretroviral therapy were not better than triple combination antiretroviral therapy in treatment naive people with HIV. This finding lends support to current guidelines recommending the triple regimen as first line treatment. Further trials on this topic should be conducted only when new research is justified by adequate systematic reviews of the existing evidence. However, this study cannot exclude the possibility that quadruple cART would be better than triple cART when new classes of antiretroviral drugs are made available.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Feng Q, Zhou A, Zou H, et al. Quadruple versus triple combination antiretroviral therapies for treatment naive people with HIV: systematic review and meta-analysis of randomised controlled trials. BMJ. 2019. PMID: 31285198. doi:10.1136/bmj.l4179

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。